NLRP3 and Parkinson disease: Furthermore, we reported that hMSCs inhibited the proinflammatory cytokines and molecules of the NLRP3 inflammasome, a crucial inflammatory mechanism of PD progression and a novel therapeutic target of PD treatment, suggesting that the anti-inflammation-mediated neuroprotection of hMSCs might be through inhibiting the NLRP3 inflammasome.